VEGFA and neoplasm: Historically, the maximum tolerated dose (MTD) has been used for the clinical development of drugs targeting the VEGF pathway [212,216] with high-dose, prolonged anti-VEGF therapy associated with lower levels of tumor perfusion and increased hypoxia [183].